Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen

Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen

286728

Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen

People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS), taking place virtually Feb. 25–27. “For people living with a chronic disease such as MS,…

You must be logged in to read/download the full post.